A study [46,47] on neurodegenerative disease biomarkers in CSF suggests that YKL-40 is expanding its relevance as a pathological and physiological biomarker that not only distinguishes AD patients from HCs but also predicts the progression of dementia from preclinical stages to late stages [48]. Here, CHI3L1 is linked to neurodegenerative disease.